In pancreatic surgery patients, octreotide reduced complications versus placebo (15.6 versus 29.2 per cent, P = 0.01).
In plain wordsIn pancreatic surgery patients, complications occurred in 15.6% with octreotide versus 29.2% with placebo.
- Peptide
- Octreotide
- Outcome
- DecreasePancreatic surgery complications
- Study
n = 252
- Comparator
- Placebo
- Outcome group
- Adverse events · Gastrointestinal
- Studied dose
- 0.1 mg every 8 h · subcutaneousAs given in this study (human).
Measurements
- Proportion of patients with complications
- 15.6%
- octreotide group
- Proportion of patients with complications
- 29.2%
- placebo group
Source sentences
The proportion of patients with complications was significantly lower in the group treated with octreotide than in the placebo group (15.6 versus 29.2 per cent, P = 0.01).
1 context sentence(design, population, supporting numbers)
A placebo-controlled double-blind multicentre study, with randomization into parallel groups, was performed to determine whether perioperative subcutaneous administration of octreotide 0.1 mg every 8 h reduces the rate of complications specifically related to pancreatic surgery.